In a striking return to the global stage, He Jiankui, the scientist infamous for creating the first gene-edited babies, is once again making headlines. At a conference in Hong Kong in 2018, He unveiled his groundbreaking work, which aimed to modify the genomes of three girls to provide them immunity against HIV. This revelation shocked the scientific community and ignited ethical debates worldwide.
He Jiankui’s journey took a severe turn when a Chinese court sentenced him to three years in prison for his unethical research practices. Following his release in 2022, He has set his sights on rehabilitating his career and pushing the boundaries of gene editing further. His ambitions now extend to developing a gene therapy for Duchenne muscular dystrophy while simultaneously exploring human embryo editing to combat Alzheimer’s disease.
A New Direction in Research
Since his release, He has claimed to have made significant progress in his work. He asserts that a pharmaceutical company has partnered with him on his research for Duchenne muscular dystrophy, and he has garnered interest from various investors eager to fund his endeavors. Operating from a newly established lab in Beijing, He has been vocal on social media about his vision, portraying himself as a pioneer and a transformative figure in the field of genetics.
Despite the controversies surrounding his past, He has embraced a bold persona online, humorously referring to himself as “China’s Frankenstein” and “Oppenheimer in China.” His social media presence reflects a blend of confidence and defiance, as he shares images of himself in lab settings and whimsical portrayals that challenge conventional views of scientific ethics.
The Quest for Gene-Edited Babies
In conversations about his work, He maintains that the scientific community should pivot towards producing more gene-edited babies, suggesting a trial involving hundreds of cases to further explore the potential of genetic modifications. He expresses confidence in the health of the original trio of gene-edited girls, asserting that they are thriving and that their families are supportive of his work.
Yet, He acknowledges the challenges of navigating a scientific landscape that remains largely hostile to germline editing. With regulations banning such practices in many countries, including China and the United States, He’s exploration into this controversial area is fraught with obstacles.
A Focus on Alzheimer’s
Highlighting his latest research focus, He has turned his attention to Alzheimer’s disease, motivated by a desire to replicate the APP-A673T mutation found in some Icelandic populations. This genetic alteration reportedly confers protection against Alzheimer’s, leading He to propose introducing this mutation into future generations. However, he is currently limited to experimentation with human cell lines and has not yet begun working directly with embryos.
He’s bold ambitions for Alzheimer’s research are fueled by a desire to effect substantial change in the world of genetic engineering. He argues that while some researchers pursue enhancements like IQ alterations, his work is centered on disease prevention—an ethical line he is keen to uphold.
Funding and Ethical Concerns
Despite his past legal troubles, He claims to have raised significant funds for his lab, totaling approximately 50 million yuan, with no government grants involved. His funding comes from private donors, some of whom are motivated by personal connections to diseases like Alzheimer’s. However, the implications of wealthy individuals funding such research raise ethical questions about access and equity in gene editing.
As he looks to the future, He has indicated a desire to conduct clinical trials, particularly in regions where regulations may be less restrictive, such as South Africa. He has expressed optimism about the receptiveness of South African authorities to his proposals, despite the ongoing legal and ethical complexities surrounding his past.
Navigating Controversy
He’s approach to research is unapologetically direct. He maintains that the primary goal should be the improvement of patient health and happiness, casting aside concerns about ethics and geopolitical implications. This stance, however, is likely to attract scrutiny, given the historical context of his previous work and the ongoing debates about the moral implications of gene editing.
He has asserted that transparency is key to his future endeavors, sharing his research plans openly on social media and inviting scrutiny. Yet, the evolution of public opinion and regulatory frameworks will play a crucial role in determining the trajectory of his work.
Looking Ahead
The future of He Jiankui’s research remains uncertain. He anticipates a timeline of two years to complete preliminary studies on animal models before seeking regulatory approval for human trials. His ultimate goal is ambitious: to create genetically edited embryos capable of preventing major diseases, potentially ushering in a new era of health and longevity.
As He navigates this complex landscape, he faces questions about the ethical boundaries of his work. The line between disease prevention and enhancement will continue to be a focal point of debate within the scientific community and beyond.
Conclusion
He Jiankui’s return to gene editing raises profound questions about the ethics and implications of his work. As he aims to reshape the landscape of genetic research, the balance between innovation and responsibility will be critical. His journey underscores the ongoing dialogue surrounding gene editing, emphasizing the need for cautious yet progressive exploration in the realm of human genetics.
- He Jiankui aims to advance gene therapy for Duchenne muscular dystrophy.
- His focus has shifted to developing gene editing techniques to prevent Alzheimer’s disease.
- The future of his research hinges on navigating complex ethical and regulatory landscapes.
- He advocates for transparency in his work to foster public trust.
- The intersection of wealth and gene editing presents potential ethical dilemmas.
Read more → www.wired.com